MISTIE III, an international phase 3 clinical trial, was part of a long-term, ongoing effort to define successful treatment for ICH, and was recently presented as a late-breaking session at the 2019 ISC in Honolulu in February and published in The Lancet.
- The MISTIE III intervention seeks to remove blood from the brain through minimally invasive surgery and intermittent dosing of alteplase. The study premise is that by removing the blood clot faster than natural removal, injury to the brain will be reduced and the patient’s long-term prognosis will improve.
- The MISTIE III trial is the culmination of the thrombolysis program spanning over 20 years of work by the trial Principal Investigators (PIs).
- Interpret the results from the MISTIE III trial
- Construct a rational approach to the patient with an ICH
- Evaluate the comparative effectiveness of minimally invasive ICH therapies
- Recommend future steps in the study and surgical treatment of ICH